Teva Introduces Generic of Vesicare to Treat Overactive Bladder

April 22, 2019, 3:57 PM

Teva Pharmaceutical launched a generic version of VESIcare (solifenacin succinate) tablets, 5 mg and 10 mg, in the U.S.

  • Indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency

Link to Statement: Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States

©2019 Bloomberg L.P. All rights reserved. Used with permission

To read the full article log in.

Learn more about a Bloomberg Law subscription.